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Abstract
Shwachman-Diamond syndrome (SDS) is a rare autosomal recessive disease which affects
1/168,000 newborns in Italy with a mean of 3.0 new cases/year. SDS is caused by mutations in
the Shwachman-Bodian-Diamond syndrome (SBDS) gene, which encodes for the homonymous
protein SBDS, whose exact function is still unknown. SBDS protein has been reported to play a role
in eukaryotic ribosome biogenesis. Thus, SDS is considered a ribosomopathy. The pathology is
characterized by multiple-organ impairment involving bone marrow failure, exocrine pancreatic
insufficiency, skeletal malformations, hepatic and cognitive disorders. Neutropenia and impaired
neutrophil chemotaxis, which in turn cause recurrent infections, are reported in young children.
Furthermore, 15-20% of SDS patients develop myelodysplastic syndrome (MDS), with increased
risk of acute myeloid leukemia (AML) progression, which represent the main cause of mortality.
However, the exact pathologic mechanism whereby loss of SDBS function could lead to the
specific SDS hematological issues remains unclear. We recently reported, for the first time to the
best of our knowledge, that the mammalian Target of Rapamycin (mTOR) and Signal Transducer
and Activator of Transcription (STAT)-3 pathways are hyper-activated in B cells, PMNs and,
mostly, in monocytes obtained from SDS patients (Bezzerri V et al, Sci Rep 2016, in press). Since
mTOR and STAT3 activation are associated with neutrophil development and AML, this finding
could at least partially explain the onset of the hematological issues. Here we show a further
Phospho flow analysis of mTOR and STAT3 pathways activation in otherlymphocytes subsets,in
particular in CD8+/CD4+ T cells and NK cells obtained from five SDS patients. We found that
STAT3 S727 is the most phosphorylated site in CD8+ and CD4+ T cells (more than twice than the
healthy control cells, each). Furthermore, mTOR (S2448) is hyper-phosphorylated in CD8+ and
CD4+ T cells derived from SDS patients. Median fluorescence intensity shifted from 220 ± 25
(healthy controls) to 405 ± 29 (SDS patients) in CD8+ T cells and from 350 ± 132 (healthy
controls) to 590 ± 150 (SDS patients) in CD4+ T cells, similarly to results obtained from
Monocytes and B cells. NK seems to be less responsive to mTOR/STAT3 activation than B and T
cells. Importantly, mTOR inhibitor rapamycin is able to reduce both mTOR and STAT3 activation,
with different efficacy, in a cell type-dependent manner. In particular, rapamycin strongly reduces
both mTOR and STAT3 S727 phosphorylation in CD8+ and CD4+ T cells. Thus, these results
suggest a role of mTOR/STAT3 pathways in both myeloid and lymphoid lineages of SDS blood
cells. Since several drugs approved by FDA and EMA targeting the JAK-STAT and mTOR pathways
have been currently evaluated for the treatment of different forms of hematological malignancies,
this work could open a wider scenario into the current SDS therapeutic approaches.
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